Seelos Therapeutics (SEELQ) AI Stock Analysis

• Market Cap: $112.00
• Dividend Yield: N/A
• Average Volume (3M): 8.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 25.28
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,124,121
• 10 Day Avg. Volume: 2,464
• 30 Day Avg. Volume: 8,686
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 101.47K
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: ― N/A
• Price Target: ―
• Action: N/A
• Date: ―

Positive Factors

Pipeline Potential

Seelos' focus on CNS disorders and rare diseases positions it well in niche markets with high unmet needs, potentially leading to successful drug approvals and partnerships.

Negative Factors

Negative Stockholders' Equity

Negative equity suggests liabilities exceed assets, posing solvency risks and necessitating financial restructuring to ensure long-term viability.

Seelos Therapeutics Business Overview & Revenue Model

Company Description

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfoli...

Read more

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfoli...

How the Company Makes Money

Seelos Therapeutics generates revenue primarily through partnerships, collaborations, and potential licensing agreements related to its pharmaceutical development programs. As a clinical-stage company, it does not yet have products on the market, ...

Read more

Seelos Therapeutics generates revenue primarily through partnerships, collaborations, and potential licensing agreements related to its pharmaceutical development programs. As a clinical-stage company, it does not yet have products on the market, ...

Seelos Therapeutics Financial Statement Overview

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	―	―	―	―	―
Gross Profit	2.20M	―	―	―	151.00K
EBITDA	-37.75M	-73.47M	-64.45M	-18.94M	-51.23M
Net Income	-37.88M	-73.53M	-66.05M	-19.10M	-51.26M
Balance Sheet
Total Assets	5.42M	22.75M	83.50M	17.49M	11.10M
Cash, Cash Equivalents and Short-Term Investments	―	―	―	―	―
Total Debt	14.23M	20.12M	18.96M	9.72M	0.00
Total Liabilities	38.93M	33.36M	26.18M	14.92M	11.10M
Stockholders Equity	―	―	―	―	―
Cash Flow
Free Cash Flow	-23.91M	-61.60M	-48.99M	-20.91M	-19.30M
Operating Cash Flow	-23.91M	-61.60M	-48.99M	-20.91M	-19.30M
Investing Cash Flow	―	―	―	―	―
Financing Cash Flow	―	―	―	―	―

Seelos Therapeutics Technical Analysis

• Last Price: 0.18

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEELQ, the sentiment is undefined. The current price of 0.18 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for SEELQ.

Seelos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SEELQ	―	$112.00	―	113.13%	―	―	―
GRI	46 Neutral	$3.90M	-0.36	-199.52%	―	―	97.37%
SCNI	44 Neutral	$1.72M	-0.20	―	―	99.48%	-474.47%
DRMA	42 Neutral	$4.99M	-0.63	-203.36%	―	―	93.30%
ENVB	41 Neutral	$8.17M	-0.45	-262.78%	―	―	82.92%